David Schaaf
Technik-/Wissenschafts-/F&E-Leiter bei PDS BIOTECHNOLOGY CORPORATION
Profil
David Schaaf is currently the Vice President-Medical Affairs at PDS Biotechnology Corp.
He previously worked as the Vice President-Medical Affairs at Zogenix, Inc. Schaaf has a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Stanford University.
Aktive Positionen von David Schaaf
| Unternehmen | Position | Beginn |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2022 |
Ehemalige bekannte Positionen von David Schaaf
| Unternehmen | Position | Ende |
|---|---|---|
| ZOGENIX, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von David Schaaf
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Stanford University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
